About Providence Therapeutics
Providence Therapeutics is a company based in Calgary (Canada) founded in 2015 by Eric Marcusson and Brad Sorenson. Providence Therapeutics has raised $10.44 million across 13 funding rounds from investors including Gates Foundation and NGen. Providence Therapeutics offers products and services including mRNA Medicines Platform, INTENT LNP Platform, Manufacturing Platform, and Pipeline in Oncology. Providence Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, Moderna, C4 Therapeutics, Erasca and MiRagen, among others.
- Headquarter Calgary, Canada
- Founders Eric Marcusson, Brad Sorenson
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$10.44 M (USD)
in 13 rounds
-
Latest Funding Round
$711.63 K (USD), Series A
May 06, 2025
-
Investors
Gates Foundation
& 1 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Providence Therapeutics
Providence Therapeutics offers a comprehensive portfolio of products and services, including mRNA Medicines Platform, INTENT LNP Platform, Manufacturing Platform, and Pipeline in Oncology.
Platform for rapid development of mRNA-based vaccines
LNP system for mRNA delivery in therapeutics
System for efficient mRNA therapeutics manufacturing
Pipeline focused on mRNA vaccines for cancer treatment
People of Providence Therapeutics
Unlock access to complete
Funding Insights of Providence Therapeutics
Providence Therapeutics has successfully raised a total of $10.44M across 13 strategic funding rounds. The most recent funding activity was a Series A round of $711.63 thousand completed in May 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Providence Therapeutics
Providence Therapeutics has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Gates Foundation and NGen.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Charitable foundation investments on poverty reduction and healthcare
|
Locked | Locked | Locked | |
|
Advanced manufacturing and technology are advanced by NGen foundation.
|
Locked | Locked | Locked |
Investor details for Providence Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Providence Therapeutics
Investment portfolio details for Providence Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Providence Therapeutics
Detailed financials for Providence Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Providence Therapeutics Comparisons
Peer comparison for Providence Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Providence Therapeutics
Providence Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Moderna, C4 Therapeutics, Erasca and MiRagen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
Detailed competitors of Providence Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Providence Therapeutics
Complete news archive for Providence Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Providence Therapeutics
Providence Therapeutics was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Providence Therapeutics is headquartered in Calgary, Canada. It is registered at Calgary, Alberta, Canada.
Brad Sorenson is the current CEO of Providence Therapeutics. They have also founded this company.
Providence Therapeutics is a funded company, having raised a total of $10.44M across 13 funding rounds to date.
Providence Therapeutics was established in 2015 in Calgary, Canada, within the biotechnology sector. mRNA-based therapeutics are focused on by the company for cancer and COVID-19 applications. Vaccines are tailored to individual patients using tumor-specific mutations, aiming to trigger immune responses. T-cell activation is promoted to target and eliminate cancer cells. Specific products, including PTX-COVID19-B and PTX-COVID19-LT, have been created for COVID-19 management.
Providence Therapeutics's top competitors include Moderna, Jazz Pharmaceuticals and C4 Therapeutics.
Providence Therapeutics offers mRNA Medicines Platform, INTENT LNP Platform, Manufacturing Platform, and Pipeline in Oncology.
Providence Therapeutics has 2 investors. Key investors include Gates Foundation, and NGen.